A detailed history of Ted Buchan & CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ted Buchan & CO holds 29,611 shares of BMY stock, worth $1.39 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares
29,611
Previous 27,225 8.76%
Holding current value
$1.39 Million
Previous $1.26 Billion 5.97%
% of portfolio
0.52%
Previous 0.5%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$43.31 - $48.98 $103,337 - $116,866
2,386 Added 8.76%
29,611 $1.34 Billion
Q2 2025

Aug 13, 2025

BUY
$44.12 - $59.6 $171,538 - $231,724
3,888 Added 16.66%
27,225 $1.26 Billion
Q1 2025

May 13, 2025

SELL
$53.9 - $63.11 $19,404 - $22,719
-360 Reduced 1.52%
23,337 $1.42 Billion
Q4 2024

Feb 12, 2025

BUY
$51.92 - $59.94 $74,764 - $86,313
1,440 Added 6.47%
23,697 $1.34 Billion
Q3 2024

Nov 01, 2024

BUY
$39.66 - $51.75 $882,712 - $1.15 Million
22,257 New
22,257 $1.15 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.5B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ted Buchan & CO Portfolio

Follow Ted Buchan & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ted Buchan & CO, based on Form 13F filings with the SEC.

News

Stay updated on Ted Buchan & CO with notifications on news.